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left ventricular systolic dysfunction: a
comprehensive cardiovascular magnetic
resonance study
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Abstract
Background: Most patients with implantable cardioverter-defibrillator (ICD) implantation fail to utilize the device
resulting in increasing societal costs and patient exposure to device morbidity. We sought to determine whether
volumetric cardiovascular magnetic resonance (CMR) left ventricular (LV) spherical remodeling predicts future
ventricular arrhythmias in primary ICD patients with reduced LV ejection fraction (EF).
Methods: Sixty-eight consecutive patients with transthoracic echocardiographic LVEF <35% referred for CMR prior
to ICD implantation for primary prevention of sudden death were identified. Sphericity index was measured as the
ratio of LV end-diastolic volume (from cine short axis stack) to the volume of a sphere with a LV end-diastolic 4-
chamber length diameter.
Results: During a median follow-up of 55 months (interquartile range; 28–88), 15 patients (22%) received
appropriate ICD therapy. Multivariable Cox’s proportional hazard modeling identified increased CMR-derived
sphericity index as the strongest independent predictor of appropriate ICD therapy (hazard ratio [HR], 1.09; 95%
confidence interval [CI], 1.02 to 1.16; p = 0.007). In addition, dichotomized volumetric CMR-derived sphericity index
≥0.57 carried a 4-fold hazard risk for appropriate ICD therapy, controlling for age and LVEF (HR, 4.49; 95% CI, 1.53 to
13.21; p = 0.006). When sphericity index, LVEF and mass index were used in combination, important incremental
prognostic information was achieved (net reclassification improvement, 0.42; 95% CI, 0.06 to 0.77).
Conclusions: The combined assessment of LV geometry, mass index and systolic function may provide incremental
prognostic information regarding ventricular arrhythmia requiring appropriate ICD therapy in primary prevention
patients with reduced LVEF.
Keywords: Cardiomyopathies, Cardiovascular magnetic resonance, Implanted cardioverter-defibrillator, Left
ventricular ejection fraction, Primary prevention, Sphericity index, Ventricular arrhythmia
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Background
The implanted cardioverter-defibrillator (ICD) is an
established therapy for reducing mortality in patients
with life-threating ventricular arrhythmia (VA) [1, 2].
Current guidelines for primary prevention ICD in-
cludes symptoms of heart failure and reduced left
ventricular (LV) ejection fraction (LVEF) [3–5], but
only a small percentage of primary prevention ICD
recipients actually receive appropriate ICD therapy [6, 7]
resulting in increasing societal costs and patient mor-
bidity. If ICD therapy is to be used in a more cost-
effective and lower morbidity manner, identifications
of variables more predictive of appropriate ICD ther-
apy are needed.
Late gadolinium enhancement (LGE) cardiovascular
magnetic resonance (CMR) is the gold standard for the
assessment of regional myocardial fibrosis and may help
predict VA and sudden cardiac death (SCD) [8–12]. Het-
erogeneous LGE scar but not LGE volume is predictive
for VA [10], but reproducible measurement of heteroge-
neous LGE scar is difficult [13]. Although most CMR
studies give the highest priority to the assessment of
LGE scar tissue characteristics, 2D transthoracic echo-
cardiographic adverse LV remodeling, as well as LV rela-
tive wall thickness are also associated with VA [14–17].
Cine CMR is accurate, reproducible, and widely consid-
ered the non-invasive gold standard for morphological
and functional assessment of the LV. However, no data
are currently available regarding the association between
CMR-derived LV geometric parameters and VA risk. Ac-
cordingly, the purpose of this study was to evaluate
whether easily derived LV geometry metrics provide
additive predictive value for the prediction of future VA
in patients with reduced LVEF receiving primary preven-
tion ICD therapy.
Methods
Study population
We retrospectively identified 71 consecutive patients
who had undergone ICD implantation for primary SCD
prevention who had a comprehensive CMR study before
ICD implantation. Subjects were identified by querying
the Beth Israel Deaconess Medical Center clinical CMR
and ICD databases from April 2004 to December 2014.
Exclusion criteria were: 1) idiopathic outflow tract ven-
tricular tachycardias, 2) Brugada, and Long QT syn-
dromes, 3) hypertrophic, inflammatory, infiltrative, and
arrhythmogenic cardiomyopathies. Ischemic etiology
was defined as the presence of any epicardial coronary
artery dimeter stenosis >70%, a history of myocardial in-
farction, or a subendocardial based LGE pattern. Patient
demographics and clinical follow-up records from the
hospital electronic medical records were reviewed. The
study was carried out with Beth Israel Deaconess
Medical Center Institutional Review Board approval
which waived written informed consent.
Image acquisition
All CMR images were acquired on a 1.5 Tesla scanner
(Achieva 1.5 T, Philips Medical Systems, Best,
Netherlands) equipped with a 5-element or 32-element
cardiac coil. The CMR protocol included cine and LGE.
To assess LV/right ventricular (RV) myocardial function,
geometry and mass, 10 to 12 short-axis stack cine im-
ages and 4-chamber long axis image were acquired using
a cine balanced steady state free precession sequence
(slice thickness, 8-mm; gap, 2-mm, in-plane spatial reso-
lution 2 × 2 mm, 30 ms temporal resolution) [18]. Ten
to 20 min after injection of 0.1–0.2 mmol/kg of Gd-
DTPA (Magnevist; Bayer Schering, Berlin, Germany) or
Gd-BOPTA (MultiHance; Bracco Imaging SpA, Milan,
Italy), short- and long-axis 2D inversion recovery LGE
images were acquired using a breath-hold, segmented in-
version-recovery sequence (8-mm slice thickness, 2-mm
inter-slice gap, TR, 4.2 ms; TE, 1.8 ms; FA, 20°; FOV,
320 × 320 mm2; matrix, 160 × 160; and spatial resolution
of 2 mm2). In 35 patients, LGE was performed using a 3D
phase sensitive inversion recovery sequence (PSIR) (5-mm
slice thickness, TR, 4.2 ms; TE, 1.8 ms; FA, 15°; FOV,
320 × 320 mm2; acquisition matrix, 176 × 156; and spatial
resolution,1.8 × 2.0 mm2).
Image analysis
CMR images were analyzed by a investigator blinded to
ICD therapy using commercial workstations (Extend MR
WorkSpace, version 2.3.6.3, Philips Healthcare, OsiriX
environment, Pixmeo, Geneva, Switzerland). At end-
diastole and end-systole, epi- and endocardial LV bor-
ders were manually traced from contiguous short-axis
cine images covering the LV apex to mitral valve plane
to calculate LV and RV end-diastolic volume (EDV) and
end-systolic volume, stroke volume, and ejection fraction
(EF). LV mass was calculated as the sum of the myocardial
volume multiplied by the specific gravity (1.05 g/mL) of
myocardial tissue. Sphericity index was calculated as the
ratio of the LV EDV to the volume of a sphere with the
diameter of the LV end-diastolic long axis from a 4-
chamber cine image (=LV volume/[LV long axis length
[3]×π/6]) [19, 20]. Relative wall thickness (RWT) was
computed as the ratio of LV anteroseptal plus inferolateral
wall thickness to end-diastolic cavity dimension measured
at the slice immediately basal to the papillary muscles
[21]. RWT_2 was also calculated as 2 times inferolateral
wall divided LV end-diastolic diameter (Fig. 1). On LGE
images, the presence or absence of LGE was visually
assessed. LGE volume was assessed using a custom
software developed in Matlab (MathWorks, Natick,
Massachusetts, USA), which enables manual segmentation
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of scarred myocardium and normal remote region and
quantifies LGE region using thresholding techniques. For
each short-axis cross section, after the endocardial and
epicardial borders were traced, a region-of-interest was
defined in the normal remote myocardium without any
artifact. The software calculated mean and standard devi-
ation (SD) of remote region signal intensity (SI) and
thresholds of all pixels with SI greater than mean + 2, 4,
or 6SD of remote region, and reported a total LGE vol-
ume. Heterogeneous scar was defined as the difference be-
tween 2SD and 4SD (2-4SD), between 4SD and 6SD (4-
6SD), and between 2SD and 6SD (2-6SD).
Follow-up
Patients were implanted with a conventional or a biven-
tricular ICD device at the discretion of the implanting
physician and without knowledge of sphericity index,
RWT or RWT_2. All devices were programmed for both
anti-tachycardia pacing and shock with three zones of
therapy including shock for ventricular fibrillation (VF),
anti-tachycardia pacing followed by shock for fast ven-
tricular tachycardia (VT), and a monitored zone for
slower VT. Exact therapy settings were adjusted at the
discretion of the implanting physician. Devices were in-
terrogated at 1 and 3 months after implantation and
every 6 months thereafter in the Device Clinic, during
which the device was interrogated, and adjudication of
stored ICD electrograms was performed by an electro-
physiologist blinded to CMR findings (HI). The primary
end point for our study was the delivery of appropriate
ICD therapy for VT, VF, or sustained VT > 30-s duration
as documented by the device and recorded in the pa-
tient’s online medical record.
Statistical analysis
Statistical analyses were performed using SPSS (v19,
International Business Machines, Inc., Armonk, New
York, USA) and R version 3.2.3 (R Project for Statistical
Computing). Continuous variables are expressed as
mean ± standard deviation (SD) or median [quartiles] as
appropriate, and compared using an unpaired Student’s
t-test or Mann-Whitney nonparametric test if not nor-
mally distributed. Categorical variables were reported as
counts and percentages, and compared using a chi-
square test. To compare the relationship between the
sphericity index and LVEF, a regression analysis was per-
formed, and an analysis of covariance was used to test
for equality of the regression slopes between patients
with and without appropriate ICD therapy. All tests were
2 sided and p value <0.05 considered significant. Kaplan-
Fig. 1 Measurements of sphericity index and relative wall thickness. Determination of (a) left ventricular (LV) sphericity index; LV end-diastolic
volume (EDV), derived by cine short axis cardiovascular magnetic resonance, is divided by volume of a sphere with diameter equal to LV 4ch end-diastolic
length. b relative wall thickness (RWT); LV anteroseptal wall thickness (SWT) plus inferolateral wall thickness (ILWT) is divided by LV end-diastolic diameter
(EDD) from the short-axis slice immediately basal to the papillary muscles. RWT_2 is calculated as 2 × ILWT divided by LV EDD
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Meier curves were used to estimate the distribution of
time to the first episode of appropriate ICD therapy or
sustained VT. Differences between time-to-event curves
were compared with the log-rank test. Univariable Cox
regression models were used to assess the association
between each variable and the primary end point. For
multivariable modeling, using the rule of thumb of hav-
ing between 5 and 10 outcomes per predictor (we had
15 with appropriate ICD therapy), we decided to include
2 most significant variables from the univariable models
(LVEF and sphericity index) and 1 covariate (age). We
then used stepwise-forward selection which yielded only
sphericity index in the final model. From this final
model, we then searched for the optimal threshold of
sphericity index (0.57) that yielded the largest area under
the receiver operating characteristic (ROC) curve. Using
this threshold, we then dichotomized the scale of spher-
icity index into binary and assessed the associations of
sphericity index ≥0.57 to appropriate ICD therapy ad-
justed to age and LVEF. All reported associations in this
study are hazard ratios (HR) and their corresponding
95% confidence intervals (CI). Reclassification of patients
was determined using net reclassification improvement
analysis for appropriate ICD therapy and obtained by
adding sphericity index and LV mass index (LVMI) sta-
tus to the model based on LVEF. Because no conven-
tional cut-off values exist for the onset of ICD therapy in
such population, risk categories were used to stratify pa-
tients into low-risk (0% to <10%), intermediate risk (10%
to <20%) and high-risk (≥20%) categories. Categorical
net reclassification improvement was computed together
with integrated discrimination improvement.
Results
Patient population
Of the 71 identified patients, 3 patients (4%) were lost to
follow-up and were excluded, leaving 68 patients for the
final analysis. Their clinical and CMR characteristics are
summarized in Tables 1 and 2. The majority were men
(74%) with almost half (46%) having an ischemic cardio-
myopathy and one third received a biventricular ICD.
Sixty-six patients (97%) had LV dilatation (LVEDV index
≥95 ml/m2 in men i ≥ 78 ml/m2 in female). Sphericity
index moderately and positively correlated with LVEDVI
(r = 0.30, p = 0.02) and negatively correlated with LVEF
(r = −0.45, p < 0.001), but did not correlate with LVMI
(r = 0.17, p = 0.17).
During a median follow-up of 55 months (interquartile
range; 28–88), 15 patients (22%) received appropriate
ICD therapy. Appropriate ICD therapies were delivered
in 11/45 (24%) with conventional ICDs and 4/23 (17%)
with biventricular ICDs (p = 0.51). There was a trend for
patients with an ischemic cardiomyopathy to receive ap-
propriate ICD therapy (32% vs 14%, p = 0.06). Patients
with and without appropriate ICD therapy had similar
baseline age, gender, history of hypertension, diabetes
mellitus and dyslipidemia (all p = NS), while patients
that received appropriate ICD therapy tended to have a
higher NYHA functional class (p = 0.05). There was a
trend for higher LV end-systolic volume and lower LVEF
in patients with appropriate ICD therapy (p = 0.04 and
0.003, respectively). Patients with ICD therapy had sig-
nificantly lower RVEF (p = 0.02). LVMI was significantly
higher in patients with appropriate ICD therapy com-
pared with that in patients without ICD therapy
(p = 0.01). In addition, LV sphericity index was signifi-
cantly higher in patients with appropriate ICD therapy
(p = 0.001). Figure 2 shows representative cases from is-
chemic cardiomyopathy with and without increased
sphericity index. The presence and any extent of LGE
using different thresholding (2SD, 4SD, and 6SD) were
not associated with receiving appropriate ICD therapy
(p = 0.11, 0.13, 0.18 and 0.17, respectively). There was a
trend for heterogeneous scar (2-4SD) to more likely re-
ceive appropriate ICD therapy (p = 0.09). RWT was not
associated with the presence of LGE (Fig. 3).
Table 1 Patients clinical characteristics
Characteristics All patients No appropriate
ICD therapy
Appropriate
ICD therapy
P-value
(n = 68) (n = 53) (n = 15)
Age, yrs 63 ± 12 63 ± 12 66 ± 10 0.38
Male gender, n (%) 50 (74) 37 (70) 13 (87) 0.19
Ischemic cardiomyopathy (%) 31 (46) 21 (40) 10 (67) 0.06
Received biventricular ICD, n (%) 23 (34) 19 (36) 4 (27) 0.51
BSA, m2 1.95 ± 0.25 1.94 ± 0.25 1.98 ± 0.23 0.64
Hypertension (%) 51 (75) 38 (72) 13 (87) 0.24
Diabetes mellitus (%) 21 (31) 15 (28) 6 (40) 0.39
Dyslipidemia (%) 42 (62) 33 (62) 9 (60) 0.87
Serum creatinine, mg/dl 1.09 ± 0.25 1.06 ± 0.25 1.17 ± 0.21 0.16
QRS duration, ms 125 ± 31 123 ± 33 131 ± 24 0.39
NYHA functional class, n (%) 0.05
I 3 (4) 2 (4) 1 (7)
II 25 (37) 23 (43) 2 (13)
III 37 (55) 26 (49) 11 (73)
IV 3 (4) 2 (4) 1 (7)
Medication use, n (%)
ACEI or ARB 62 (91) 47 (89) 15 (100) 0.17
Beta-blocker 59 (87) 46 (87) 13 (87) 0.99
Antiarrhythmics 6 (9) 5 (9) 1 (7) 0.74
Antiplatelet agents 53 (78) 39 (74) 14 (93) 0.10
Diuretics 19 (28) 15 (28) 4 (27) 0.90
Length of follow-up, months 58 ± 34 57 ± 36 59 ± 39 0.83
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor
blockers, BSA body surface area, ICD implantable cardioverter-defibrillator,
NYHA New York Heart Association, Values in parentheses represent percents
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LV geometry and appropriate ICD therapy
Univariable and multivariable analyses of clinical and
CMR parameters for appropriate ICD therapy are sum-
marized in Table 3. In multivariable analysis, increased
LV sphericity index was the strongest independent pre-
dictor of appropriate ICD therapy (hazard ratio [HR];
1.09; 95% confidence interval [CI] 1.02 to 1.16,
p = 0.007). Although reduced LVEF was an important
predictor of appropriate ICD therapy in univariate ana-
lysis, LVEF was no longer significant in multivariate ana-
lysis because of significant negative correlation with
sphericity index (r = −0.45, p < 0.001) (Fig. 4). The ROC
curves showed a sphericity index of ≥0.57 to be the opti-
mal cut-off points for appropriate ICD therapy, with
67% sensitivity, 76% specificity and area under the ROC
curve of 0.75 (95% CI 0.61 to 0.89). A sphericity index of
≥0.57 identified patients with a 4-fold hazard risk for ap-
propriate ICD therapy, after adjusting for age and LVEF.
Kaplan-Meier curves showed significantly lower ICD
therapy-free survival in patients with sphericity index
values ≥0.57 (p = 0.003) (Fig. 5). The c-statistic of LVEF
and LVMI for predicting appropriate ICD therapy were
0.74 (95% CI 0.59 to 0.89) and 0.68 (95% CI 0.52 to
0.84), respectively. The optimal LVEF threshold of 30%
determined by ROC curves provided 80% sensitivity and
57% specificity for appropriate ICD therapy. When
sphericity index as well as LVMI, was combined with
LVEF, we observed a greater c-statistic than either vari-
able used individually (c-statistic = 0.81; 95% CI 0.66 to
0.95, Delong’ test; p = 0.13). Furthermore, the addition
of sphericity index and LVMI values to LVEF yielded 4
correct (up) reclassifications and 2 incorrect (down)
reclassifications in the 15 patients of receiving ICD ther-
apy. Additionally, 19 correct (down) reclassifications and
4 incorrect (up) reclassifications occurred in the 53 pa-
tients who did not receive ICD therapy. Overall, the in-
tegration of sphericity index and LVMI values provided
the improvement in risk stratification (net reclassifica-
tion index (NRI) 0.42; 95% CI 0.06 to 0.77, p = 0.02). Re-
duced RVEF appeared more likely to predict appropriate
ICD therapy (HR; 1.04, p = 0.054) and RVEF <40% (by
dichotomous analysis) demonstrated a strong univariate
association with appropriate ICD therapy (HR; 3.92; 95%
CI 1.42 to 10.85, p = 0.009). However, RVEF did not sig-
nificantly predict appropriate ICD therapy beyond LVEF.
Discussion
In this retrospective study of 68 consecutive patients re-
ferred for CMR prior to primary prevention ICD im-
plantation, we demonstrate that: 1) CMR LV sphericity
index is the strongest independent predictor of ventricu-
lar arrhythmias requiring appropriate ICD therapy, 2)
CMR-derived sphericity index ≥0.57 is associated with a
higher risk of appropriate ICD therapy adjusted for age,
gender, and LVEF, 3) the integration of sphericity index
to LV function assessment provides additional prognos-
tic information regarding appropriate ICD therapy. Im-
portantly, sphericity index can be easily derived and
without a cost of additional scan time or need for gado-
linium contrast.
Echocardiographic (echo)-derived LV sphericity is a
marker of LV systolic dysfunction and exercise tolerance
in heart failure [19, 22], an independent predictor of ad-
verse cardiovascular events in ischemic [23] or non-
ischemic cardiomyopathy [24], and is associated with in-
creased LV wall stress [25]. Moreover, higher wall stress
can alter the electrophysiologic properties through an
increase in dispersion of action potential duration and
membrane recovery [26, 27] and contribute as trigger
for VA, although anatomical substrates for re-entrant
Table 2 Patients CMR characteristics
Characteristics All patients No appropriate
ICD therapy
Appropriate
ICD therapy
P-value
(n = 68) (n = 53) (n = 15)
LVDd (SAX), mm 67.6 ± 6.7 67.3 ± 6.6 68.7 ± 7.4 0.45
LV length (4 chamber), mm 97.8 ± 8.9 98.2 ± 9.5 96.1 ± 6.7 0.45
Sphericity index 0.54 ± 0.08 0.52 ± 0.07 0.60 ± 0.08 0.001
Septal wall thickness, mm 8.6 ± 2.6 8.4 ± 2.4 9.1 ± 3.1 0.39
Inferolateral wall thickness, mm 7.4 ± 2.0 7.4 ± 1.9 7.5 ± 2.6 0.84
RWT_2P 0.22 ± 0.06 0.22 ± 0.06 0.22 ± 0.08 0.99
RWT_AP 0.24 ± 0.06 0.24 ± 0.06 0.24 ± 0.08 0.77
LV EDV, ml 268.6 ± 80.3 261.6 ± 76.8 293.6 ± 89.9 0.17
LV EDVI, ml/m2 137.5 ± 36.0 134.0 ± 31.7 149.6 ± 47.5 0.14
LV ESV, ml 192.5 ± 78.0 182.2 ± 71.9 228.9 ± 89.8 0.04
LV EF, % 30.1 ± 9.4 31.8 ± 8.9 23.9 ± 8.7 0.003
LV mass, g 155.3 ± 46.4 147.5 ± 40.3 182.7 ± 57.0 0.009
LV mass index, g/m2 80.1 ± 22.6 76.5 ± 19.5 92.6 ± 28.5 0.014
LV mass/LV EDV, g/ml 0.59 ± 0.13 0.58 ± 0.13 0.63 ± 0.13 0.16
LV LGE, n (%) 38 (56) 27 (51) 11 (73) 0.11
LV LGE2SD, g 26.9 ± 33.5 23.8 ± 31.9 38.0 ± 38.2 0.13
LV LGE4SD, g 20.9 ± 29.1 19.1 ± 28.9 27.4 ± 30.1 0.18
LV LGE6SD, g 16.2 ± 24.5 15.1 ± 24.7 20.2 ± 24.5 0.17
Heterogeneous LGE(2-4SD), g 6.6 ± 9.8 5.5 ± 8.6 10.6 ± 12.8 0.09
Heterogeneous LGE(4-6SD), g 4.7 ± 6.8 4.0 ± 6.0 7.1 ± 8.9 0.10
Heterogeneous LGE(2-6SD), g 11.3 ± 15.3 9.5 ± 13.0 17.8 ± 20.8 0.12
RV EDV, ml 156.6 ± 58.5 156.4 ± 59.6 157.3 ± 56.5 0.96
RV EDVI, ml/m2 77.9 ± 19.9 77.5 ± 18.3 79.2 ± 25.4 0.77
RV ESV, ml 80.9 ± 42.0 77.5 ± 38.2 92.9 ± 53.0 0.21
RV EF, % 48.9 ± 12.5 50.3 ± 12.0 43.8 ± 13.3 0.08
RV EF < 40, n (%) 17 (25) 9 (17) 8 (53) 0.02
Values in parentheses represent percents
Dd diastolic dimension, EDV end-diastolic volume, EDVI end-diastolic volume
index, EF ejection fraction, ESV end-systolic volume, ICD implantable
cardioverter-defibrillator, LGE late gadolinium enhancement, LV left ventricular,
RV right ventricular, RWT relative wall thickness, SAX short axis transection, SD
standard deviation
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VA have been mostly attributed to LV architectural
changes, such as scar and interstitial fibrosis. Our study
results are consistent with the recent study by Levine et
al. showing that 2D transthoracic echo sphericity index
predicts appropriate ICD therapy in patients with re-
duced LVEF [15]. However, selection of imaging planes
and accuracy of 2D echo are dependent on operator ex-
perience, and limited acoustic windows may not allow
accurate long axis views of the heart. In addition, biplane
volumetric analysis by 2D echo depends on geometric
assumptions and is subject to image-plane positioning
errors. Thus, relatively small measurement errors can
lead to some differences in sphericity index cut-off value
between biplane 2D echo and volumetric CMR.
In a recent 2D echo study by Biton et al. [14], de-
creased RWT was associated with a higher risk of VA
and cardiac death, leading to the conclusion that RWT
is directly correlated with wall thickness and low RWT
might mirror the extent of LV fibrosis/scarring. In
contrast, the 2D echo results of the VALIANT study in-
dicated higher RWT was related to an increased risk of
cardiovascular death, MI and sudden death in post-MI
population [28]. We found the impact of RWT had not
been shown clearly, although patients with increased
LVM/LVEDV appeared likely to receive appropriate ICD
therapy. Furthermore, our observation was that the pres-
ence of LGE was not associated with regional wall thick-
ness as well as RWT. This finding supports the results
of Shah et al. who found myocardial thinning does not
necessarily indicate scar tissue and might improve after
revascularization in patients with coronary artery disease
[29]. In ischemic cardiomyopathy, the extreme nonuni-
formity of the LV wall thickness in combination with
marked variability in the extent or degree of adverse re-
modeling would be expected to contribute to consider-
able RWT overlap.
Our results showed the presence and extent of LGE
was not a predictor for appropriate ICD therapy. Al-
though focal scar evident by the presence and extent of
LGE is known to be associated with increased risk of VA
and ICD therapy [7, 8, 30–32], the electrophysiologic
substrate for ventricular arrhythmias in patients with is-
chemic and non-ischemic cardiomyopathy is substan-
tially different. Diffuse myocardial fibrosis, myocyte
disarray, and membrane abnormalities likely form the
substrate responsible for VA in patients with non-
ischemic cardiomyopathy [33]. Therefore, heterogeneous
patient population of ischemic and non-ischemic cardio-
myopathy patients undergoing ICD implantation and
LGE assessment may explain the inconsistency between
the current study and previous studies of ischemic car-
diomyopathy. Similar to our previous study [10], we also
found that heterogeneous scar rather than presence and
extent of LGE had univariate association with appropri-
ate ICD therapy. These findings suggest that heteroge-
neous scar is a more sensitive marker of appropriate
Fig. 2 Representative ischemic cardiomyopathy cases with and without increased sphericity index. Example cases (a) 68 year-old man with prior
inferior myocardial infarction who received appropriate ICD therapy. Larger sphericity index of 0.73 as well as severe LV dysfunction (LVEF = 18%)
was documented although LGE-CMR image showed only a small area of focal subendocardial inferior wall enhancement. b 61 year-old man with
an extensive anteroseptal myocardial infarction who did not receive ICD therapy. Sphericity index was 0.48, however there is marked dyskinesis
with LVEF 21% on the LV apex and transmural LGE were observed
Fig. 3 Individual subject relative wall thickness data of patients with
and without LGE. There were no significant differences in relative
wall thickness (RWT_AP and RWT_2P) between LGE positive vs. LGE
negative group
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ICD therapy. Myocardial tissue characterization using T1
or extracellular volume (ECV) mapping allows for as-
sessment of diffuse myocardial fibrosis. We have recently
reported the native T1 is useful for predicting VA in
non-ischemic cardiomyopathy [34]. Further studies are
needed to confirm whether myocardial tissue
characterization using newer technique, i.e. T1 or ECV
mapping, provide incremental value to LGE and LV
function/geometry for the prediction of future VA risk in
patients with reduced LVEF receiving primary preven-
tion ICD therapy.
Interestingly, we found RVEF <40% carried a 4-fold
unadjusted hazard risk for appropriate ICD therapy,
which implies a clinical importance for the accurate as-
sessment of RV function by CMR. However, RV
dysfunction was mainly related to indices of LV function
and not associated with VA beyond LVEF and the pres-
ence of LGE. This finding may reflect the presence of
other subclinical conditions, such as RV ischemia or
post-capillary pulmonary hypertension that affect RV
function and have negative impact on VA.
Study limitations
Our study has several limitations. It is a retrospective
study with a relatively small sample size, thus, the results
should be interpreted cautiously. We studied patients re-
ferred for CMR prior to undergoing primary prevention
ICD implantations spanning a period of 10 years. Heart
failure management might have changed over the course
of this follow-up period. We assessed CMR parameters
Table 3 Univariable and multivariable Cox’s proportional hazard models for the association with appropriate ICD therapy
Univariate analysis Multivariate analysis model 1 Multivariate analysis model 2
Characteristics HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Age,yrs 1.01 0.96–1.06 0.63 1.02 0.97–1.08 0.41 1.02 0.97–1.08 0.43
Male 3.22 0.72–14.42 0.13
Biventricular ICD 0.49 0.15–1.58 0.23
Ischemic cardiomyopathy 2.42 0.83–7.10 0.11
Hypertension 2.16 0.49–9.59 0.31
Diabetes mellitus 2.04 0.72–5.78 0.18
Dyslipidemia 0.77 0.27–2.24 0.63
Serum creatinine, per 0.1 increase 1.19 0.97–1.46 0.10
QRS duration 1.00 0.99–1.02 0.72
NYHA ≥ III 2.65 0.75–9.42 0.13
CMR parameters
Sphericity index, per 0.01 increase 1.09 1.02–1.16 0.007 1.09 1.02–1.16 0.007
Sphericity index > 0.57 4.49 1.53–13.21 0.006 4.49 1.53–13.21 0.006
RWT, per 0.01 increase 1.01 0.94–1.10 0.75
LV EDVI 1.01 1.00–1.02 0.18
LV ESV 1.01 1.00–1.01 0.039
LV EF, per 1% decrement 1.09 1.03–1.15 0.005 1.07 0.99–1.13 0.08 1.07 0.99–1.13 0.08
LV mass index 1.01 1.00–1.02 0.039
LV mass/LV EDV 4.56 0.11–198.25 0.43
LV LGE 2.45 0.78–7.72 0.13
LV LGE2SD 1.01 1.00–1.03 0.14
LV heterogeneous LGE(2-4SD) 1.07 1.02–1.12 0.01
RV EDVI 1.01 0.98–1.03 0.58
RV ESV 1.01 1.00–1.02 0.10
RV EF, per 1% decrement 1.04 1.00–1.08 0.054
RV EF < 40% 3.92 1.42–10.85 0.009
Variables given are mean ± SD or N (%) or median (interquartile range)
Abbreviation as in Tables 1 and 2
Model 1 included sphericity index, LVEF and age. Model 2 included sphericity index > 0.57, LVEF and age
HR (hazard ratio) refers to the ratio of hazards of the presence of the characteristic to the reference (absence), or to the change of 1 unit (continuous variable)
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at a single time. Changes in sphericity index may be
more predictive of future VA than a single baseline
measurement. Device choice and programming was not
standardized and was left to the discretion of the
operator.
Conclusion
CMR-derived sphericity index may be an important pre-
dictor of VA and provide additive risk stratification for
primary prevention ICD in patients with LV systolic dys-
function. Prospective, large multicenter studies are
warranted to examine this easily obtained CMR param-
eter in the selection of patients for primary prevention
ICD therapy.
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